Physician profile
Nam Hee Om
NPI 1992891311
$2,001.78
in general payments reported to CMS, 2019-2025
14 companies · $47.74 in 2025
The $47.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $408 · 2021: $391 · 2022: $295 · 2023: $260 · 2025: $47.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $377.68 | 2019-2023 | Mounjaro, Jardiance |
| Amarin Pharma, INC. | $344.02 | 2019-2023 | |
| Abbvie INC. | $336.45 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $217.63 | 2019-2022 | |
| Novo Nordisk INC | $154.34 | 2020-2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $133.55 | 2019-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $91.11 | 2019-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $72.05 | 2019 | |
| Amgen INC. | $69.95 | 2019-2022 | |
| Pfizer INC. | $58.40 | 2019 | |
| Scpharmaceuticals INC. | $30.00 | 2025 | |
| Gilead Sciences, INC. | $25.58 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nam Om listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.